These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19546601)

  • 1. Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost.
    Cheng JW; Li Y; Wei RL
    Ophthalmic Res; 2009; 42(2):99-105. PubMed ID: 19546601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
    Wang RF; Serle JB; Gagliuso DJ; Podos SM
    J Glaucoma; 2000 Dec; 9(6):458-62. PubMed ID: 11131752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials.
    Zabriskie N; Netland PA;
    Adv Ther; 2003; 20(2):92-100. PubMed ID: 12836809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
    Nguyen QH; Earl M
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
    Day DG; Hollander DA
    Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials.
    Webers CA; van der Valk R; Schouten JS; Zeegers MP; Prins MH; Hendrikse F
    Ophthalmology; 2007 Jan; 114(1):40-6. PubMed ID: 17070584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
    Simmons ST;
    Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of medical intervention for normal tension glaucoma.
    Cheng JW; Cai JP; Wei RL
    Ophthalmology; 2009 Jul; 116(7):1243-9. PubMed ID: 19450880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy.
    Konstas AG; Mikropoulos D; Dimopoulos AT; Moumtzis G; Nelson LA; Stewart WC
    Br J Ophthalmol; 2008 Nov; 92(11):1498-502. PubMed ID: 18703549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE; Lai J
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
    Fechtner RD; McCarroll KA; Lines CR; Adamsons IA
    J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
    Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
    JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
    Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
    Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.